Skip to main content

BillionToOne, Inc. (BLLN)

New York Stock Exchange Healthcare Medical - Diagnostics & ResearchView data quality →
51.4Fair

ValueMarkers Composite Index

Top 38%#27,795 of 44,707
Undervalued

34% below intrinsic value ($121)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-2.17
Investigate
Altman
15.28
Safe
DCF Value
$121
Undervalued
ROIC
2.6%
Low
P/E
1109.2
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

BillionToOne, Inc. (BLLN) — VMCI valuation read

BillionToOne, Inc. sits at VMCI 51/100, with the Healthcare sector median at 50. That 1-point spread is the first thing to note on BLLN: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on BLLN are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on BLLN: BLLN trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of 1.5x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

BLLN rose 2.0% over the trailing 7 days, with a +5.7% read on a 30-day basis.

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.

CEO: Oguzhan Atay620 employeesUSwww.billiontoone.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in BLLN’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.